期刊
EUROPEAN JOURNAL OF CANCER
卷 37, 期 16, 页码 2015-2022出版社
PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/S0959-8049(01)00216-7
关键词
doxorubicin; head and neck cancer; pegylated liposome; radiotherapy; response; toxicity
类别
A phase II trial of pegylated liposomal doxorubicin (Caelyx (TM)) as induction chemotherapy was conducted in 20 patients with treatment-naive squamous cell cancer of the head and neck (SCCHN). 10 patients received two cycles of Caelyx (TM) (40 mg/m(2)) every 3 weeks before starting radical radiotherapy (RT). Subsequently, consecutive groups of 3 patients received a third escalating dose of Caelyx (TM) (10, 15 and 20 mg/m(2)) 3 days before RT. 9 of 18 (50%, 95% confidence intervals (CI): 26-74%) evaluable patients responded to Caelyx (TM), with 11 responses in 26 (42%, 95% Cl: 24-62%) evaluable sites (three complete responses (12%), eight partial responses (31%)). There was no grade 3/4 haematological, mucosal or cardiac toxicity. Nausea and vomiting were minimal. There were no drug-related RT delays. Local RT-induced toxicity was not increased. Caelyx (TM) has significant activity against SCCHN and warrants further investigation in this disease. In view of its tumour targeting properties and activity at moderate doses, it may be useful in concomitant chemoradiotherapy strategies for SCCHN. (C) 2001 Elsevier Science Ltd. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据